Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. (Q53064246)

11 May 2018

title

Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. (English)

1 reference

11 May 2018

1 reference

1 reference

Marc C Chamberlain

1

1 reference

11 May 2018

publication date

1 March 2014

1 reference

11 May 2018

Journal of Neuro-Oncology

published in

1 reference

11 May 2018

volume

118

1 reference

11 May 2018

issue

1

1 reference

11 May 2018

page(s)

155-162

1 reference

11 May 2018

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

cites work

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Temozolomide as salvage treatment in primary brain lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Prospective trial on topotecan salvage therapy in primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Rituximab monotherapy for patients with recurrent primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Novel Agents in Hodgkin Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Bendamustine: rebirth of an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Salvage therapy with single agent bendamustine for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11060-014-1411-8

Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma

21 January 2018

1 reference

12 December 2020

Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma

1 reference

12 December 2020

Treatment of relapsed central nervous system lymphoma with high-dose methotrexate

1 reference

12 December 2020

High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system

1 reference

12 December 2020

Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?

1 reference

12 December 2020

PCV salvage chemotherapy for recurrent primary CNS lymphoma

1 reference

12 December 2020

Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma

1 reference

12 December 2020

10.1007/S11060-014-1411-8

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018